Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to $7.5 million.

  • Cytosorbents' Cash & Equivalents rose 1593.85% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 1593.85%. This contributed to the annual value of $3.3 million for FY2024, which is 7678.88% down from last year.
  • Latest data reveals that Cytosorbents reported Cash & Equivalents of $7.5 million as of Q3 2025, which was up 1593.85% from $10.2 million recorded in Q2 2025.
  • Cytosorbents' Cash & Equivalents' 5-year high stood at $68.5 million during Q1 2021, with a 5-year trough of $3.3 million in Q4 2024.
  • In the last 5 years, Cytosorbents' Cash & Equivalents had a median value of $14.1 million in 2023 and averaged $25.1 million.
  • Per our database at Business Quant, Cytosorbents' Cash & Equivalents surged by 15945.75% in 2021 and then tumbled by 7678.88% in 2024.
  • Cytosorbents' Cash & Equivalents (Quarter) stood at $52.1 million in 2021, then crashed by 57.53% to $22.1 million in 2022, then plummeted by 36.19% to $14.1 million in 2023, then plummeted by 76.79% to $3.3 million in 2024, then soared by 129.76% to $7.5 million in 2025.
  • Its Cash & Equivalents stands at $7.5 million for Q3 2025, versus $10.2 million for Q2 2025 and $11.6 million for Q1 2025.